Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 2, 2002

View Archived Issues

New data on a fixed combination of calcipotriol/betamethasone dipropionate in psoriasis

T-cell depletion by alefacept reported effective in psoriatic lesions

Antidiabetic efficacy of GLP-1 derivative NN-2211 in minipigs

Preclinical antitumor activity of FK-228

Kiadis and Biofrontera collaborate to develop treatments for neuropathic pain

Progress reported in Lorantis and PowderJect's allergy collaboration

Takeda and Albany Molecular Research begin drug discovery research

FDA approves OTC Claritin for allergies, approvable letter for hives

Novel insulin mimetics from plant origin described by Suntory

New factor Xa inhibitors in early development at BMS

P&G discovers series of melanocortin MC3/MC4 ligands

Novel beta3-adrenoceptor agonists for obesity, diabetes, etc.

Japan Tobacco presents new inhibitors of hematopoietic cell phosphatase

Sumitomo researchers identify new chemopreventive agents

Kyorin designs new series of potent, selective and orally active human PPARalpha activators

U.K. team designs potent inhibitors of CDK1/CDK2 as potential anticancer agents

SAR on a novel series of pyrrolobenzodiazepine antitumor agents

Aclacinomycin analogues produced by Finnish scientists using combinatorial biosynthesis

FR-167653, a potential antiinflammatory agent

Simultaneous inhibition of angiogenesis and tumor growth with human MAb targeting integrins

Preclinical profile of MEN-91507, a candidate for the treatment of inflammatory diseases

Data support use of TLK-286 in combination chemotherapy

Aventis returns dexlipotam rights to Viatris

YKP-581 selected for advancement

Kissei licenses KUC-7483 to Boehringer Ingelheim

MIV Therapeutics and Endovasc form Stentgenix joint venture

DN-101 evaluated in androgen-independent prostate cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...